Matches in SemOpenAlex for { <https://semopenalex.org/work/W2189616077> ?p ?o ?g. }
- W2189616077 abstract "Glutamate, a nonessential amino acid, is the major excitatory neurotransmitter in the central nervous system. As such, glutamate has been shown to play a role in not only neural processes, such as learning and memory, but also in bioenergetics, biosynthetic and metabolic oncogenic pathways. Glutamate has been the target of intense investigation for its involvement not only in the pathogenesis of benign neurodegenerative diseases (NDDs) such as Parkinson’s disease, Alzheimer’s disease, schizophrenia, multiple sclerosis, and amyotropic lateral sclerosis (ALS), but also in carcinogenesis and progression of malignant diseases. In addition to its intracellular activities, glutamate in secreted form is a phylogenetically conserved cell signaling molecule. Glutamate binding activates multiple major receptor families including the metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs), both of which have been implicated in various signaling pathways in cancer. Inhibition of extracellular glutamate release or glutamate receptor activation via competitive or non-competitive antagonists decreases growth, migration and invasion and induces apoptosis in breast cancer, melanoma, glioma and prostate cancer cells. In this review, we discuss the current state of glutamate signaling research as it relates to benign and malignant diseases. In addition, we provide a synopsis of clinical trials using glutamate antagonists for the treatment of NDD and malignant diseases. We conclude that in addition to its potential role as a metabolic biomarker, glutamate receptors and glutamate-initiated signaling pathways may provide novel therapeutic opportunities for cancer." @default.
- W2189616077 created "2016-06-24" @default.
- W2189616077 creator A5015517692 @default.
- W2189616077 creator A5043472830 @default.
- W2189616077 date "2013-01-01" @default.
- W2189616077 modified "2023-09-27" @default.
- W2189616077 title "Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic" @default.
- W2189616077 cites W1490297017 @default.
- W2189616077 cites W1506357578 @default.
- W2189616077 cites W1530165143 @default.
- W2189616077 cites W1547526327 @default.
- W2189616077 cites W1548398500 @default.
- W2189616077 cites W1559213768 @default.
- W2189616077 cites W1559359038 @default.
- W2189616077 cites W1576656296 @default.
- W2189616077 cites W1582103295 @default.
- W2189616077 cites W1592375995 @default.
- W2189616077 cites W1872072116 @default.
- W2189616077 cites W187700432 @default.
- W2189616077 cites W1878739498 @default.
- W2189616077 cites W1897589155 @default.
- W2189616077 cites W1964628210 @default.
- W2189616077 cites W1966698297 @default.
- W2189616077 cites W1971324155 @default.
- W2189616077 cites W1972298818 @default.
- W2189616077 cites W1972362927 @default.
- W2189616077 cites W1972582694 @default.
- W2189616077 cites W1972619445 @default.
- W2189616077 cites W1974740818 @default.
- W2189616077 cites W1981292076 @default.
- W2189616077 cites W1988025172 @default.
- W2189616077 cites W1990266086 @default.
- W2189616077 cites W1993254026 @default.
- W2189616077 cites W1996280923 @default.
- W2189616077 cites W1997533142 @default.
- W2189616077 cites W1997855586 @default.
- W2189616077 cites W1999777934 @default.
- W2189616077 cites W2000388202 @default.
- W2189616077 cites W2000831325 @default.
- W2189616077 cites W2002766055 @default.
- W2189616077 cites W2003130870 @default.
- W2189616077 cites W2005614483 @default.
- W2189616077 cites W2007051067 @default.
- W2189616077 cites W2008720843 @default.
- W2189616077 cites W2011324232 @default.
- W2189616077 cites W2012199810 @default.
- W2189616077 cites W2012928472 @default.
- W2189616077 cites W2013514700 @default.
- W2189616077 cites W2014309354 @default.
- W2189616077 cites W2016558185 @default.
- W2189616077 cites W2017117125 @default.
- W2189616077 cites W2018120348 @default.
- W2189616077 cites W2018150950 @default.
- W2189616077 cites W2018169163 @default.
- W2189616077 cites W2019372876 @default.
- W2189616077 cites W2022809683 @default.
- W2189616077 cites W2023081218 @default.
- W2189616077 cites W2023560077 @default.
- W2189616077 cites W2023794469 @default.
- W2189616077 cites W2024795810 @default.
- W2189616077 cites W2025160847 @default.
- W2189616077 cites W2025854374 @default.
- W2189616077 cites W2029009477 @default.
- W2189616077 cites W2029219396 @default.
- W2189616077 cites W2031121711 @default.
- W2189616077 cites W2034253224 @default.
- W2189616077 cites W2035000040 @default.
- W2189616077 cites W2037111632 @default.
- W2189616077 cites W2037852973 @default.
- W2189616077 cites W2039498326 @default.
- W2189616077 cites W2040827479 @default.
- W2189616077 cites W2041116269 @default.
- W2189616077 cites W2042211936 @default.
- W2189616077 cites W2042651745 @default.
- W2189616077 cites W2043166209 @default.
- W2189616077 cites W2044638164 @default.
- W2189616077 cites W2046173010 @default.
- W2189616077 cites W2046390430 @default.
- W2189616077 cites W2047884170 @default.
- W2189616077 cites W2049025142 @default.
- W2189616077 cites W2049958331 @default.
- W2189616077 cites W2053899262 @default.
- W2189616077 cites W2054063927 @default.
- W2189616077 cites W2054173142 @default.
- W2189616077 cites W2054708422 @default.
- W2189616077 cites W2056753605 @default.
- W2189616077 cites W2062312459 @default.
- W2189616077 cites W2062904839 @default.
- W2189616077 cites W2063382533 @default.
- W2189616077 cites W2063759211 @default.
- W2189616077 cites W2066715779 @default.
- W2189616077 cites W2069760615 @default.
- W2189616077 cites W2070490477 @default.
- W2189616077 cites W2071421185 @default.
- W2189616077 cites W2072953729 @default.
- W2189616077 cites W2082273024 @default.
- W2189616077 cites W2084200464 @default.
- W2189616077 cites W2086120407 @default.
- W2189616077 cites W2087678487 @default.
- W2189616077 cites W2090273457 @default.